first
part
overview
describ
life
cycl
influenza
viru
pharmacolog
action
current
avail
drug
second
part
provid
overview
molecular
mechan
target
stillexperiment
drug
treatment
manag
influenza
briefli
distinguish
compound
antiinfluenza
activ
target
influenza
viru
protein
gene
molecul
target
host
compon
essenti
viral
replic
propag
latter
compound
develop
quit
recent
among
first
group
focu
especi
hemagglutinin
channel
neuraminidas
inhibitor
second
group
compound
may
pave
way
person
treatment
influenza
manag
combin
therapi
also
discuss
recent
decad
antivir
molecul
influenza
viru
infect
avail
condit
use
human
anim
outbreak
inde
season
pandem
outbreak
antivir
drug
usual
administ
monotherapi
sometim
uncontrol
manner
farm
anim
led
emerg
viral
strain
display
resist
especi
compound
amantadan
famili
reason
particularli
import
develop
new
antivir
drug
influenza
virus
inde
although
vaccin
power
mean
mitig
effect
influenza
epidem
antivir
drug
use
particularli
delay
spread
new
pandem
virus
therebi
enabl
manufactur
prepar
larg
quantiti
pandem
vaccin
addit
antivir
drug
particularli
valuabl
complic
case
influenza
especi
hospit
patient
write
overview
mine
variou
databas
includ
embas
pubchem
drugbank
chemic
abstract
servic
patent
repositori
first
part
overview
describ
life
cycl
influenza
viru
pharmacolog
action
current
avail
drug
second
part
overview
molecular
mechan
target
stillexperiment
drug
treatment
manag
influenza
figur
show
attack
point
sever
potenti
antivir
drug
antivir
drug
research
particularli
activ
field
new
approach
develop
briefli
distinguish
compound
antiinfluenza
activ
directli
target
influenza
viru
protein
gene
molecul
target
host
compon
essenti
viral
replic
propag
among
former
group
focu
especi
hemagglutinin
ha
matrix
protein
neuraminidas
na
inhibitor
hai
nai
latter
molecul
implement
quit
recent
may
pave
way
person
treatment
manag
influenza
moreov
expect
inhibit
host
factor
singl
molecul
andor
complex
mechan
intracellular
signal
cascad
pathway
may
act
differ
influenza
viru
strain
may
less
prone
emerg
drug
resist
inhibit
viral
compon
therapi
combin
two
compound
belong
group
differ
group
also
discuss
write
overview
mine
variou
chemic
databas
includ
embas
pubchem
drugbank
chemic
abstract
servic
ca
well
patent
repositori
clinic
trial
registri
also
scan
extant
review
consult
gray
literatur
book
proceed
confer
abstract
poster
congress
commun
order
increas
coverag
antiinfluenza
drug
includ
present
articl
regard
search
strategi
use
mine
approach
similar
describ
eyer
hruska
time
languag
filter
appli
best
knowledg
articl
constitut
comprehens
uptod
overview
antiinfluenza
compound
literatur
use
also
work
bibliographi
map
review
scholar
research
field
along
paper
databas
current
design
develop
access
ciriit
institut
websit
effect
antivir
compound
interfer
attach
entri
influenza
viru
host
cell
includ
triterpenoid
glycyrrhiz
acid
ga
glycyrrhizin
gr
glycyrrhetin
acid
deriv
extract
licoric
present
chines
medica
gr
activ
molecul
repress
replic
well
sever
virus
deliv
approv
parenter
gr
prepar
stronger
neominophafen
c
snmc
glutamyltryptophan
ad
order
increas
activ
gr
abl
inhibit
entri
viru
host
cell
reduc
level
proinflammatori
molecul
chemokin
cxc
motif
ligand
type
interleukin
cc
chemokin
ligand
type
cc
chemokin
ligand
type
also
exert
antiapoptot
action
addit
gr
hinder
monocyt
recruit
antioxid
activ
inhibit
format
influenza
virusinduc
reactiv
oxygen
speci
ro
extens
modul
gene
express
activ
interferongamma
ifngamma
reduc
express
nuclear
factor
kappa
b
cjun
ntermin
kinas
jnk
furthermor
gr
reduc
highmobilitygroup
box
type
promis
glycyrrhizin
deriv
includ
spacerlink
analogu
ga
inhibit
influenza
viru
growth
replic
embryon
egg
moreov
use
adjuv
prepar
antiinfluenza
vaccin
triterpenoid
saponin
uralsaponin
root
glycyrrhiza
ura
lensi
exhibit
antiinfluenza
antihiv
activ
moreov
saponin
use
vaccin
adjuv
modul
express
cytokin
chemokin
triterpenoid
deriv
share
broad
antivir
action
dextran
sulphat
ds
neg
charg
sulphat
polysaccharid
besid
inhibit
viru
entri
attach
repress
hadepend
fusion
activ
nadepend
activ
howev
mutat
confer
resist
ds
describ
literatur
oxid
dextran
administ
prevent
sulphat
molecul
includ
sulphat
syalil
lipid
effect
iav
human
metapneumoviru
hmpv
picornaviru
assum
interfer
fusion
precis
natur
mechan
still
unknown
anoth
potenti
fusion
inhibitor
shown
promis
activ
rsv
lysosomotrop
agent
concanamycin
macrolid
antibiot
bafilomycin
saliphenylhalamid
n
ndicyclohexylcarbodiimid
chloroquin
inhibit
vacuolar
atpas
vatpas
reduc
endosom
acidif
lysosom
number
act
cme
pathway
unabl
block
clathrin
caveolaeindepend
endocytosi
stress
antiinfluenz
activ
compound
strongli
depend
ph
cellular
environ
scholar
report
conflict
find
vivo
effect
extract
milk
thistl
seed
known
silymarin
complex
mixtur
flavonolignan
main
compon
silibinin
activ
influenza
also
silybin
deriv
block
viru
entri
regul
autophagi
repress
format
oxid
stress
speci
trigger
activ
extracellular
signalregul
kinas
erk
mitogenactiv
protein
kinas
mapk
kinas
ikk
cascad
silybin
deriv
includ
silybin
fatti
acid
conjug
strong
antioxid
properti
compound
melaleuca
alternifolia
tea
tree
oil
tto
concentr
mac
broad
antimicrobi
activ
silico
simul
shown
compound
interfer
viru
entri
fusion
influenza
viru
potenti
compound
includ
amaryllidacea
alkaloid
lycori
radiat
lycorin
hippeastrin
hemanthamin
vittatin
also
inhibit
nucleartocytoplasm
export
ribonucleoprotein
rnp
complex
curcumin
abl
inhibit
viru
entri
ha
also
antioxid
antiinflammatori
anticanc
antivir
antibacteri
antidiabet
properti
among
other
curcumin
act
larg
array
target
curcumin
also
activ
virus
rajput
collabor
show
anim
diet
enrich
curcumin
display
improv
immun
respons
surprisingli
curcumin
deriv
exhibit
antiinfluenza
activ
extract
leav
wild
blackcurr
ribe
nigrum
folium
shown
antivir
activ
vivo
vitro
without
effect
influenza
viru
metabol
growth
prolifer
fattiviracin
recent
discov
antivir
besid
inhibit
iav
ibv
activ
hiv
hsv
vzv
lignan
exert
good
antiinfluenza
activ
germacron
molecul
purifi
rhizoma
curcuma
effect
combin
oseltamivir
akt
inhibitor
also
effect
entri
inhibitor
includ
peptid
akt
may
maxingshigantang
mxsgt
tradit
chines
herbal
decoct
everolimu
inhibitor
pathway
also
valuabl
tool
influenza
among
antiattach
drug
fludas
potenti
antiinfluenza
viru
properti
medic
prove
capabl
inhibit
human
avian
influenza
virus
preclin
studi
act
mimick
na
destroy
molecul
sialic
acid
receptor
host
cell
surfac
also
effect
naresist
influenza
strain
effect
class
hai
amid
deriv
gossypol
natur
phenol
aldehyd
extract
cotton
plant
block
dehydrogenas
famili
enzym
antivir
properti
emerg
studi
experiment
model
influenza
pneumonia
use
particular
chiral
gossypol
activ
gossypol
anoth
antivir
ha
entri
blockpeptid
ebpeptid
peptid
deriv
fibroblast
growth
factor
ebpeptid
inhibit
viru
entri
attach
effect
even
administ
postinfect
besid
repress
influenza
virus
ebpeptid
also
activ
virus
also
use
adjuv
formalininactiv
influenza
wholeviru
vaccin
trigger
phagocytosi
influenza
virion
peptid
similar
ebpeptid
flupep
fp
peptid
tkip
tkip
design
mimet
suppressor
cytokin
signal
soc
protein
involv
mediat
immun
respons
influenza
furthermor
peptid
ndfrskt
strong
antivir
properti
unknown
therapeut
characterist
molecul
bind
ha
collectin
cl
human
cl
bovin
conglutinin
confer
protect
influenza
infect
relat
group
molecul
ficolin
hficolin
lficolin
present
high
concentr
serum
bronchoalveolar
secret
bind
ha
also
na
vitro
model
protein
engin
way
becom
activ
influenza
viru
exampl
chang
collabor
design
recombin
chimer
lectin
consist
mannosebind
lectin
mbl
lficolin
howev
role
inflammatori
respons
potenti
use
human
requir
complet
analysi
recent
agglutinin
nictaba
uda
protectin
like
protectin
found
antiinfluenza
proprieti
interest
compound
bind
specif
highmannos
oligosaccharid
ha
cyanovirinn
cvn
okeef
et
al
demonstr
potent
vitro
antivir
activ
wide
rang
iav
ibv
includ
naresist
strain
though
resist
induc
mutat
affect
glycosil
site
ha
seem
aris
quit
natur
clarithromycin
cam
abl
inhibit
influenza
viru
replic
vitro
cell
cultur
appear
mechan
action
type
season
influenza
viru
recent
show
cam
reduc
express
human
influenza
viru
receptor
mucos
surfac
airway
reduc
product
nuclear
factorkb
nfkb
increas
ph
insid
endosom
norakin
triperiden
anticholinerg
drug
interact
ha
interact
may
indirect
mediat
increas
intern
ph
prelysosom
compart
howev
strain
resist
norakin
describ
also
norakin
deriv
seem
effect
antivir
compound
anoth
interest
compound
nitazoxanid
use
treatment
protozo
bacteri
infect
activ
hepat
influenza
virus
rotavirus
thiazolid
act
posttransl
level
select
block
matur
viral
ha
stage
preced
resist
endoglycosidas
h
digest
thu
interf
ha
intracellular
traffick
insert
host
plasma
membran
key
step
correct
assembl
exit
viru
host
cell
bacillu
intermediu
ribonucleas
binas
show
good
antiinfluenza
activ
binas
ha
interact
sialic
acid
cell
surfac
penetr
host
cell
subsequ
viral
rna
releas
cleav
binas
high
mannosebind
lectin
hmbl
power
influenza
hiv
inhibitor
rutin
quercetin
relat
compound
extract
elderberri
fruit
sambucu
nigra
l
ha
inhibitor
xylopin
rosmaricin
amin
group
interact
ha
theaflavin
tf
black
tea
strong
antiinfluenza
activ
inhibit
ha
reduc
level
thu
exert
antiinflammatori
antiapoptot
action
inhibitor
basic
divid
group
first
includ
compound
deriv
lead
amantadin
rimantadin
hydroxyl
deriv
second
includ
nonadamantan
deriv
promis
drug
influenza
virus
compound
specif
design
import
mutant
ion
channel
iav
regard
molecul
put
capabl
block
ion
pump
gasparini
cowork
recent
conduct
field
investig
effect
omeprazol
famili
compound
ofc
influenzalik
ill
ili
result
show
subject
treat
omeprazol
famili
compound
display
lower
risk
catch
ili
adj
ci
nontreat
subject
molecular
dock
molecular
dynam
md
simul
common
method
search
new
potenti
drug
seem
confirm
find
protein
protein
data
bank
pdb
code
simul
embed
dipalmitoylphosphatidylcholin
dppc
membran
complex
ligand
amantadin
rimantadin
use
posit
control
omeprazol
put
ligand
thermodynam
integr
method
use
order
estim
bind
free
energi
ligand
freeenergi
calcul
impli
omeprazol
potent
antivir
drug
also
anoth
studi
suggest
antivir
properti
omeprazol
ebolaviru
polyamin
spermin
spermidin
putrescin
recent
identifi
intrins
rectifi
potassium
channel
inde
protein
bind
site
polyamin
differ
amantadin
bind
site
polyamin
quit
recent
exploit
design
antiinfluenza
vaccin
spiropiperidin
inhibitor
deriv
appear
promis
act
amantadineresist
virus
particular
seem
activ
among
natur
product
pinanamin
deriv
good
influenza
activ
substitut
salicylanilid
appear
promis
antivir
agent
particular
niclosamid
approv
human
use
helminth
infect
besid
activ
influenza
virus
also
shown
antineoplast
broad
antivir
effect
activ
sarsrel
coronaviru
human
rhinoviru
hrv
lysosomotrop
agent
also
alreadi
discuss
compound
includ
molecul
obtain
tto
alreadi
mention
cleavag
ha
block
protein
compound
also
inhibit
necessari
proteas
given
great
import
proteas
viral
replic
cycl
mani
author
direct
research
toward
antiproteas
medic
could
block
least
mitig
consequ
ha
cleavag
ha
also
block
natur
product
hepatocyt
growth
factor
activ
inhibitor
sever
antiproteas
drug
studi
vitro
model
anim
human
camostat
mesil
epsilonaminocapron
acid
leupeptin
aprotinin
approv
topic
use
smallparticl
aerosol
formul
russia
theoret
advantag
antivir
activ
enzymat
activ
host
molecul
would
lead
select
resist
viral
variant
molecul
interfer
mechan
fusion
endosom
viral
membran
inde
numer
small
molecul
block
viru
infect
inhibit
conform
chang
requir
hamedi
membran
fusion
identifi
russel
et
al
demonstr
tbhq
tertbutylhydroquinon
stabil
neutral
ph
structur
way
presum
inhibit
conform
rearrang
requir
membran
fusion
furthermor
leikina
et
al
demonstr
human
lectin
inhibit
hamedi
influenza
viral
fusion
regard
compound
target
transcript
replic
vrna
one
first
drug
develop
ribavirin
rib
rib
also
known
trade
name
virazol
nucleosid
analog
mechan
action
complet
known
howev
inosin
dehydrogenas
impdh
appear
princip
target
molecul
inhibit
diminish
intracellular
concentr
gtp
thought
stop
viral
protein
synthesi
limit
vrna
replic
crotti
et
al
also
demonstr
rib
lethal
vrna
mutagen
howev
need
high
dose
drug
order
obtain
good
clinic
result
limit
use
rib
antiinfluenza
drug
recent
revis
literatur
chantack
et
al
suggest
conclus
result
benefici
use
virazol
treatment
influenza
rib
also
deliv
liposom
encapsul
muramyl
tripeptid
mtppe
antitrypsin
aat
serin
proteas
inhibitor
elastas
protein
produc
liver
express
increas
particularli
acutephas
respons
also
immunomodulatori
antiinflammatori
tissueprotect
properti
reduc
influenzarel
complic
morbid
immunomodul
aat
mediat
matur
differenti
dendrit
cell
dc
regulatori
cell
reg
activ
receptor
antagonist
induc
releas
moreov
exert
antiapoptot
effect
inhibit
role
aat
inhibit
influenza
virus
consist
clinic
observ
subject
aat
defici
expos
risk
sever
influenzarel
complic
therefor
vaccin
stachyflin
acetylstachyflin
phosphat
esther
oxo
deriv
exert
inhibitori
activ
varieti
ha
subtyp
iav
among
other
activ
subtyp
iav
ibv
metabolit
stachyflin
deriv
includ
compound
cisfus
decalin
stachyflin
compound
deliv
intranas
oral
use
peg
vehicl
howev
amino
acid
substitut
confer
resist
stachyflin
salicylamid
deriv
analogu
use
compound
thiobenzamid
deriv
good
activ
profil
particular
axial
disposit
thioamid
moieti
prove
crucial
inhibitori
activ
ulinastatin
proteas
inhibitor
also
protect
lysosom
integr
use
suggest
treatment
avian
influenza
sever
influenzarel
complic
encephalopathi
acut
respiratori
distress
syndrom
ard
inde
recent
publish
metaanalysi
shown
drug
effect
manag
acut
lung
injuri
ali
ard
ubiquitinspecif
peptidas
type
proteas
inhibitor
anoth
promis
molecul
part
interferonregul
cellular
cascad
found
one
seven
gene
predict
respons
influenza
viru
find
reproduc
liu
collabor
antivir
strategi
direct
viral
rna
polymeras
trimer
polymeras
complex
multipl
enzymat
activ
thu
target
differ
site
action
instanc
nucleosidenucleotid
compound
develop
virus
name
hiv
hbv
etc
histor
compound
moroxydin
also
activ
hsv
vzv
thoroughli
studi
molecul
favipiravir
vitro
studi
demonstr
high
antivir
potenc
drug
mous
studi
demonstr
protect
efficaci
wide
rang
influenza
virus
b
molecul
also
seem
effect
virus
recent
compound
direct
toward
antinucleas
activ
studi
seri
hydroxypyridinon
appear
antivir
activ
cell
studi
differ
kind
phytochem
scholar
identifi
famili
drug
call
marchantin
appear
interact
pa
subunit
endonucleas
attract
strategi
develop
antipolymeras
compound
appear
interf
subunit
bind
interfac
pa
well
conserv
differ
influenza
viru
strain
thu
compound
would
reduc
transcript
activ
viral
rna
polymeras
one
promis
compound
also
activ
human
cytomegaloviru
furthermor
recent
definit
bind
interfac
mean
crystallographi
prompt
research
studi
synthet
peptid
peptid
peptid
seem
inhibit
interact
azaindol
inhibitor
abl
interfer
capsnatch
activ
polymeras
complex
influenza
viru
small
gtpase
inhibitor
exhibit
similar
activ
profil
leptomycin
b
lmb
inhibit
nuclear
export
signal
ne
mediat
vrnp
export
well
nesreceptor
howev
somewhat
toxic
verdinexor
newgener
antagonist
well
toler
anim
model
seem
effect
iav
ibv
select
inhibitor
nuclear
export
sine
given
fundament
import
np
modul
replic
cycl
viru
mani
author
investig
strategi
prevent
product
moreov
molecul
prevent
function
polymer
np
monom
also
studi
exampl
nucleozin
ncz
also
block
viral
rna
protein
synthesi
target
vrnp
nuclear
export
cytoplasmat
traffick
final
result
fewer
smaller
influenza
viral
particl
releas
ncz
deriv
includ
quit
effect
compound
name
shown
inhibit
replic
influenza
viru
though
npmutant
strain
display
resist
drug
jiang
collabor
screen
peptid
librari
discov
npbind
prolinerich
peptid
particularli
effect
influenza
virus
anoth
interest
molecul
interferoninduc
protein
cycloheximid
chx
also
activ
coxsackieviru
b
actinomycin
quit
effect
chemic
intriguingli
clinic
licens
naproxen
also
appear
inhibit
function
polymer
np
monom
deriv
naproxen
also
appear
quit
promis
anoth
drug
direct
np
ingavirin
licens
russia
inde
ingavirin
interact
transport
newli
synthes
np
cytoplasm
nucleu
also
activ
parainfluenza
viru
adenovirus
human
metapneumoviru
nai
includ
peramivir
lanimamivir
deriv
baicalin
induc
autophagi
act
na
isoscutellarein
anoth
compound
inhibit
influenza
viru
sialidas
deriv
also
activ
influenza
anoth
potenti
strategi
influenza
block
protein
nonstructur
protein
import
viral
replic
cycl
inde
protein
downregul
cellular
product
ifn
furthermor
demonstr
also
modul
crucial
aspect
influenza
viru
replic
name
viral
rna
replic
viral
protein
synthesi
gener
hostcel
physiolog
final
probabl
antiapoptot
function
earli
phase
replic
mean
apoptosi
influenza
viru
replic
ambigu
although
usual
consid
cellular
antivir
defens
limit
viru
replic
therefor
influenza
virus
acquir
differ
way
procrastin
seem
host
strategi
nonetheless
cellular
proapoptot
factor
favor
effect
replic
influenza
virus
viral
protein
na
carri
proapoptot
task
furthermor
compound
act
protein
studi
perspect
peptidemedi
inhibit
propos
strategi
mitig
viral
replic
unfortun
virusspecif
approach
lead
viral
mutat
occurr
drug
resist
recent
jablonski
et
al
studi
class
molecul
deriv
compound
display
protein
inhibit
viral
replic
assay
regul
develop
dna
damag
molecul
recent
emerg
comprehens
biochem
screen
moreov
inhibit
mtor
pathway
cordycepin
extract
cordycep
genu
ascomycet
fungi
use
divers
medicin
purpos
differ
pharmacolog
action
hypothet
antivir
activ
apoptosi
play
major
role
influenza
viru
life
cycl
inde
order
replic
viru
activ
mechan
apoptosi
activ
caspas
cellular
inhibitor
apoptosi
protein
ciap
essenti
regul
cell
death
immun
nucleotidebind
oligomer
domainlik
receptor
type
bind
viral
protein
prevent
iavinduc
macrophag
apoptosi
promot
macrophag
surviv
type
ifn
signal
interestingli
compound
inhibit
enzymat
activ
could
use
antiinfluenza
antivir
inde
wurzer
et
al
shown
apoptot
activ
caspas
requir
effici
viru
product
furman
collabor
demonstr
apoptot
index
predict
biomark
influenza
vaccin
respons
howev
question
whether
apoptosi
benefici
viral
reproduct
cycl
host
cell
still
debat
moreov
hinshaw
et
al
demonstr
inhibit
apoptosi
viral
infect
influenza
viru
rnp
complex
retain
nucleu
therefor
use
caspas
inhibitor
could
good
potenti
antiinfluenza
drug
autophagi
autophagocytosi
catabol
mechan
involv
cellular
breakdown
dysfunct
cell
compon
involv
lysosom
procyanidin
antiiav
activ
lfructos
lxylulos
inhibit
influenza
viru
replic
glucosidas
glucosidas
ii
inhibitor
includ
iminosugar
alter
glycan
process
influenza
ha
na
rafmekerk
pathway
inhibitor
includ
compound
act
inhibitor
nfkb
inhibitor
includ
bortezomib
among
other
proteasom
inhibitor
also
effect
paramyxovirus
hrv
polioviru
coxsackieviru
hsv
hiv
lipid
metabol
play
fundament
role
influenza
viru
replic
membran
compon
sphingolipid
crucial
step
viral
life
cycl
attach
membran
fusion
intracellular
transport
replic
protein
sort
bud
infect
influenza
viru
stimul
phospholipas
pld
activ
antiiav
host
factor
neg
regul
traffick
viral
compon
host
cell
plasma
membran
via
substrat
acetyl
microtubul
antiinfluenza
chemic
cyclosporin
act
classic
target
name
cyclophilin
cypa
cyclophilin
b
cypb
pglycoprotein
pgp
inhibit
influenza
viru
releas
chingfangpaitusan
cfpt
similar
action
oxid
play
major
role
influenza
viru
life
cycl
replic
regard
antiinfluenza
drug
act
subsequ
variou
stage
viral
replic
format
vrnp
worth
consid
resveratrol
may
use
antiinfluenza
drug
inde
compound
could
interfer
transloc
rnp
nucleu
cytoplasm
dehydroascorb
acid
also
antivir
properti
calcitriol
prior
toor
exposur
affect
viral
clearanc
significantli
reduc
autophagi
restor
increas
apoptosi
seen
infect
constitut
level
howev
significantli
reduc
level
tumor
necrosi
factoralpha
rant
interferonbeta
ifnstimul
oh
treatment
prior
toor
infect
significantli
downregul
rna
level
public
antivir
drug
often
devot
use
statin
antiflu
drug
particular
fedson
suggest
treat
patient
affect
statin
studi
vitro
anim
field
seem
support
strategi
statin
held
act
variou
mechan
immunomodulatori
antiinflammatori
activ
interf
protein
cytoskeleton
interact
lipid
raft
reduc
avail
intracellular
cholesterol
balanc
content
cholesterol
cell
critic
replic
iav
inde
reduct
cholesterol
could
impair
infect
progeni
influenza
virus
probabl
reduc
cholesterol
content
viral
envelop
howev
studi
found
statin
ineffect
influenza
virus
extract
epimedium
koreanum
nakai
immunomodulatori
properti
also
hsv
vsv
newcastl
diseas
viru
ndv
carrageenan
extract
edibl
red
seawe
administ
nasal
spray
particular
iotacarrageenan
appear
effect
influenza
cycloferon
amixin
larifan
kagocel
ragosin
stimul
b
cell
macrophag
produc
ifnalpha
wide
use
russia
apocynin
nadph
oxidas
type
inhibitor
stimul
cell
superoxid
product
howev
certain
condit
also
act
ro
product
stimul
nonphagocyt
cell
contrast
nadph
oxidas
type
antiinflammatori
activ
inhibit
ro
product
rolipram
select
inhibitor
antidepress
properti
sertralin
select
serotonin
reuptak
inhibitor
ssri
exhibit
strong
antivir
activ
combin
oseltamivir
rational
use
belong
famili
enzym
metabol
cyclic
adenosin
monophosph
camp
cyclic
guanosin
monophosph
cgmp
commonli
found
inflammatori
immun
respons
reduc
bronchospasm
bronchoconstrict
reduc
mortal
morbid
mous
model
ssri
downregul
express
interferonalpha
tnfalpha
helper
cell
modul
immun
respons
toward
phenotyp
sphingosin
mimet
abl
fine
modul
releas
cytokin
chemokin
one
studi
neutral
antibodi
cytotox
cell
respons
seen
reduc
though
still
protect
result
infiltr
pml
macrophag
lung
markedli
reduc
thu
also
pulmonari
tissu
injuri
dc
matur
suppress
limit
prolifer
specif
antivir
cell
lung
drain
lymph
node
furthermor
effect
control
cell
accumul
lung
even
given
day
onset
influenza
viru
infect
leucomycin
macrolid
antibiot
inhibit
neutrophil
myeloperoxidas
mpo
contribut
pathogenesi
progress
sever
influenzainduc
pneumonia
mediat
product
hypochlor
acid
potent
tissu
injuri
factor
deriv
leukotrien
exert
antivir
stimulatori
activ
host
defenc
system
also
activ
hiv
rsv
coronavirus
recruit
leukocyt
foster
releas
chemokin
defensin
molecul
immunomodulatori
properti
current
investig
adjuv
vaccin
influenza
thymalfasin
zadaxin
deriv
thymosin
anoth
power
adjuv
canakinumab
ilari
block
antibodi
also
promis
compound
immunotherapi
observ
made
influenza
therapi
nonsteroid
antiinflammatori
drug
season
flu
normal
treat
overthecount
otc
drug
design
reliev
symptom
common
paracetamol
acetylsalicyl
acid
howev
contraind
individu
year
age
ibuprofen
nsaid
cough
usual
mitig
mean
drug
use
dextromethorphan
acetylcistein
activ
ingredi
inflamm
driven
innat
immun
usual
suffici
cure
diseas
howev
especi
viru
particularli
virul
pandem
immun
may
dysregul
cytokinestorm
may
give
rise
sever
form
influenza
treatment
season
pandem
influenza
therefor
utilis
appropri
time
antiinflammatori
therapi
abovement
drug
statin
naproxen
antiinflammatori
properti
howev
probabl
also
abl
exert
real
antivir
activ
light
human
case
infect
strain
lethal
case
caus
viru
need
modul
innat
immun
particular
import
inde
patient
sever
fatal
human
infect
due
viru
instanc
high
proinflammatori
respons
earli
ill
abovement
reason
literatur
often
report
vitro
anim
studi
demonstr
therapeut
util
antiinflammatori
immunemodulatori
compound
fibrat
influenza
gene
therapi
consist
modul
upregul
downregul
gene
andor
product
involv
respons
influenza
microrna
mirna
small
noncod
rna
molecul
contain
nucleotid
function
rna
silenc
rna
interfer
rnai
posttranscript
regul
gene
express
host
mirna
abl
downregul
express
viral
gene
therefor
mirna
modul
could
promis
approach
influenza
treatment
despit
difficulti
deliv
mirna
cell
effici
small
interf
rna
sirna
also
mediat
rnai
short
nucleotid
induc
sequencespecif
degrad
homolog
mrna
long
noncod
rna
lncrna
modul
variou
biolog
process
one
lncrna
particular
play
major
role
act
neg
regul
antivir
respons
nrav
downregul
influenza
infect
nrav
neg
regul
transcript
multipl
critic
interferonstimul
gene
isg
remodel
chromatin
case
compound
precis
natur
pharmacolog
activ
influenza
still
unknown
requir
research
nanoparticl
promis
nanobiotechnolog
tool
act
carrier
nonconjug
nanoparticl
silver
nanoparticl
modul
spa
spd
use
deliv
rnai
poli
gammaglutam
acid
fulleren
chitosan
ntrimethyl
chitosan
tmc
polymer
nanoparticl
also
investig
vaccin
adjuv
howev
singlewal
carbon
nanotub
swcnt
seem
increas
influenza
viru
pathogen
infect
combin
therapi
ct
divid
associ
two
drug
directli
target
viral
compon
associ
directact
viral
compound
molecul
target
host
compon
ct
may
improv
clinic
outcom
reduc
risk
respiratori
complic
mortal
morbid
reduc
risk
use
singl
drug
resist
doserel
toxic
sideeffect
may
potenti
enhanc
antivir
activ
ct
turn
divid
earli
combin
chemotherapi
ecc
sequenti
multidrug
chemotherapi
smc
furthermor
mani
studi
evalu
efficaci
combin
antiinflammatori
drug
antivir
drug
comparison
singledrug
treatment
howev
combin
therapi
instanc
combin
oseltamivir
zanamivir
simvastatin
oseltamivir
superior
monotherapi
ct
also
exploit
variou
chimer
monoclon
antibodi
human
studi
import
determin
number
age
subject
studi
standard
method
defin
possibl
correctli
evalu
antivir
potenti
compound
examin
perspect
also
import
compar
antivir
activ
hypothet
antivir
refer
drug
amantadin
oseltamivir
etc
order
ascertain
influenza
antivir
index
new
molecul
vitro
studi
also
advis
evalu
capac
antivir
studi
induc
viral
resist
field
medicin
chemistri
discoveri
develop
complet
new
molecular
entiti
nme
compound
particularli
expens
term
time
cost
research
could
therefor
carri
along
two
differ
line
designingoptimis
new
deriv
exist
lead
secondgener
nai
laninamivir
peramivir
repurposingreposit
exist
drug
new
potenti
clinic
applic
latter
approach
also
term
drug
retask
reprofil
alreadi
yield
promis
result
drug
retarget
initi
serendipit
later
systemat
develop
exploit
least
combin
advanc
biochem
biophys
bioinformat
cheminformat
techniqu
viroinformat
comput
system
biolog
suggest
ration
inhibitor
viral
transcript
replic
protein
synthesi
nuclear
export
assemblyreleas
strategi
may
emerg
gene
data
mine
regard
bao
collabor
use
priorit
gene
approach
order
find
import
gene
involv
host
resist
influenza
viru
found
respons
control
two
tnfmediat
pathway
apoptosi
tnf
signal
pathway
addit
system
pharmacometr
system
pharmacolog
could
identifi
valuabl
ct
studi
drug
synergi
secondli
avail
antiinfluenza
drug
use
appropri
manner
order
imped
mitig
phenomenon
viral
resist
regard
first
question
antiinflammatori
drug
chosen
answer
take
account
age
patient
toxic
toler
drug
efficaci
allevi
patient
symptom
obvious
therapi
initi
soon
possibl
nsaid
aspirin
subject
year
ibuprofen
naproxen
paracetamol
acetaminophen
chosen
compound
reliev
symptom
also
equilibr
patient
innat
immun
sometim
direct
indirect
antivir
effect
instanc
interest
reduc
proinflammatori
cytokin
diminish
activ
proteas
involv
ha
cleavag
addit
administr
acetylcystein
use
mucolyt
action
also
account
antioxid
activ
choic
antivir
take
account
broad
resist
influenza
virus
amantadan
drug
also
fact
monotherapi
easili
lead
emerg
novel
viral
resist
perspect
topic
drug
zanamivir
prove
gener
less
resist
viral
strain
drug
administ
oral
addit
antivir
antiproteas
drug
could
use
influenza
therapi
compound
could
advantag
inhibitor
cellular
protein
less
prone
select
resist
viral
strain
howev
born
mind
disturb
cellular
environ
order
disrupt
viral
function
could
advers
side
effect
furthermor
propos
therapeut
protocol
involv
combin
two
antivir
drawn
order
reduc
develop
drugresist
viral
strain
time
administ
lower
drug
dose
anoth
hypothesi
could
administ
two
differ
antivir
altern
final
use
antivir
veterinari
field
exampl
chicken
flock
care
control
case
combin
altern
administr
least
two
antivir
drug
rule
import
realis
impli
one
world
one
health
one
medicin
one
scienc
approach
human
veterinari
medicin
cooper
interest
global
health
increasingli
interconnect
world
